Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal cancer after chemotherapy failure.
Colon Cancer Liver Metastasis
PROCEDURE: TACE|DRUG: Irinotecan|DEVICE: eluting-bead
Tumor Response of two months, Response rate(RR), Two months post first treatment|Tumor Response of four months, Response rate(RR), four months post first treatment|Tumor Response of six months, Response rate(RR), Six months post first treatment
overall survival, overall survival(OS), From date of first treatment until the date of death from any cause, whichever came first, assessed up to 24 months|Time to intrahepatic progression, Time to intrahepatic progression(THP), From date of first treatment until the date of intrahepatic progression, whichever came first, assessed up to 24 months|Time to extrahepatic progression, Time to extrahepatic progression(TEP), From date of first treatment until the date of extrahepatic progression, whichever came first, assessed up to 24 months|Quality of life, Assesment Quality of life by EORTC QOL-C30 questionnaire, Six months post first treatment
This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal cancer after chemotherapy failure.